High Hurdle For Novartis's New Oncology Division
Executive Summary
Novartis AG has nailed its oncology colors firmly to the mast by restructuring its pharmaceuticals division to separate out cancer from the rest of its pharma business. But the changes do not disguise the need to offset the loss of patent protection for its pioneering targeted anticancer blockbuster Gleevec (imatinib).
You may also be interested in...
Novartis Takes Aim At Systemic Mastocytosis With Midostaurin
Novartis AG's novel anticancer midostaurin is looking promising in the rare indication of advanced systemic mastocytosis given positive data from a pivotal Phase II study just published in the New England Journal of Medicine.
Novartis Ups Pace On Ibrance Challenger As Ribociclib Trial Stopped Early
Novartis's Phase III MONALEESA-2 trial of its CDK4/6 inhibitor ribociclib has been stopped early on positive interim data. The study was conducted in first-line metastatic, hormone-positive breast cancer patients, a market estimated to be worth $6bn in the US alone.
Novartis Rejiggers Pharma To Favor Oncology
The Swiss pharma changes the leadership structure of its pharmaceutical division in an effort to emphasize oncology; AstraZeneca's Paul Hudson takes over the non-oncology pharma group as David Epstein leaves the company.